The structure-function relationship of activated protein C: Lessons from natural and engineered mutations

Thrombosis and Haemostasis

Volumn 106, Issue 6, 2011, Pages 1034-1045

  Wildhagen, Karin C A A ^a   Lutgens, Esther ^a,b   Loubele, Sarah T G B ^a   ten Cate, Hugo ^a   Nicolaes, Gerry A F ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Activated protein C; Anticoagulation; Cytoprotection; Mutagenesis; Structure function

Indexed keywords

ACTIVATED PROTEIN C; CALCIUM ION; CATION; PROTEIN C;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOLYSIS; BINDING AFFINITY; BINDING SITE; CALCIUM BINDING; CELL PROTECTION; DRUG EFFICACY; ENZYME BINDING; HEART INFARCTION; HEAVY CHAIN; HUMAN; LIGHT CHAIN; LUNG INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SEPSIS; SITE DIRECTED MUTAGENESIS;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; CYTOPROTECTION; FACTOR V; FACTOR VIII; GENETIC ENGINEERING; HUMANS; MUTATION; PROTEIN C; PROTEIN S; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 82555181621     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-08-0522     Document Type: Review

References (123)

1. Griffin JH, Fernandez JA, Gale AJ, et al. Activated protein C. J Thromb Haemost 2007; 5: 73-80.
2. Stearns-Kurosawa D, Kurosawa S, Mollica J, et al. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. PNAS 1996; 96: 10212-10216.
3. Mather T, Oganessyan V, Hof P, et al. The 2.8 Å crystal structure of Gla-domainless activated protein C. EMBO J 1996; 15: 6822-6831.
4. UniProtKB/Swiss-Prot, PROC_HUMAN, accession number P04070. 2011.
5. Grinnell B, Walls J, Gerlitz B. Glycosylation of human protein C affects its secretion, processing, functional activities, and activation by thrombin. J Biol Chem 1991; 266: 9778-9785.
6. Scully M, Toh C, Hoogendoorn H, et al. Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha-1-antitrypsin and alpha- 2-macroglobulin in patients with disseminated intravascular coagulation Thromb Haemost 1993; 69: 448-453.
7. Heeb M, Gruber A, Griffin J. Identification of divalent metal ion-dependent inhibition of activated protein C by alpha-2-macroglobulin and alpha-2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin and plasmin. J Biol Chem 1991; 266: 17606-17612.
8. Zhu T, Ubhayasekera W, Nickolaus N, et al. Zinc ions bind to and inhibit activated protein C. Thromb Haemost 2010; 104: 544-553.
9. Mammen EF, Thomas WR, Seegers WH. Activation of purified prothrombin to autoprothrombin I or autoprothrombin II (platelet cofactor II or autoprothrombin II-A). Throm Diath Haemorrh 1976; 5: 218-249.
10. Stenflo J. A new vitamin K-dependent protein. J Biol Chem 1976; 251: 355-363.
11. Kalafatis M, Rand M, Mann K. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-31880.
12. Nicolaes G, Tans G, Thomassen M, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 21158-21166.
13. Rosing J, Hoekema L, Nicolaes G, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 27852-27858.
14. Yegneswaran S, Wood G, Esmon C, et al. Protein S alters the active site location of activated protein C above the membrane surface. A fluorescence resonance energy transfer study. J Biol Chem 1997; 272: 25013-25021.
15. Yegneswaran S, Smirnov M, Safa O, et al. Relocating the active site of activated protein C eliminates the need for its protein S cofactor. A fluorescence resonance energy transfer study. J Biol Chem 1999; 274: 5462-5468.
16. Segers K, Dahlbäck B, Rosing J, et al. Identification of surface epitopes of human coagulation factor Va that are important for interaction with activated protein C and heparin. J Biol Chem 2008; 283: 22573-22581.
17. Nicolaes GAF, Bock PE, Segers K, et al. Inhibition of thrombin formation by active site mutated (S360A) activated protein C. J Biol Chem 2010; 285: 22890-22900.
18. Kim P, Nesheim M. Down regulation of prothrombinase by activated protein C during prothrombin activation. Thromb Haemost 2010; 104: 61-70.
19. Fay P, Smudzin T, Walker F. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 1991; 266: 20139-20145.
20. Amano K, Michnick D, Moussalli M, et al. Mutation at either Arg336 or Arg562 in factor VIII is insufficient for complete resistance to activated protein C (APC)- mediated inactivation: implications for the APC resistance test. Thromb Haemost 1998; 79: 557-563.
21. Nyberg P, Dahlbäck B, Garcia de Frutos P. The SHBG-like region of protein S is crucial for factor V-dependent APC-cofactor function. FEBS Lett 1998; 433: 28-32.
22. Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood 1999; 93: 2552-2558.
23. Thorelli E, Kaufman R, Dahlbäck B. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem 1998; 273: 16140-16145.
24. Lollar P, Parker C. pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem 1990; 265: 1688-1692.
25. Nicolaes G, Dahlbäck B. Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states. Hematol Oncol Clin North Am 2003; 17: 37-61.
26. Nicolaes GAF, Dahlbäck B. Congenital and acquired activated protein C resistance. Semin Vasc Med 2003; 3: 33-46.
27. Dahlbäck B, Villoutreix BO. Regulation of blood coagulation by the protein C anticoagulant pathway. Novel insights into structure-function relationships and molecular recognition. Vasc Biol 2005; 25: 1311-1320.
28. Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med 1983; 309: 340-344.
29. Griffin JH, Evatt B, Zimmerman TS, et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373.
30. Zorio E, Navarro S, Medina P, et al. Circulating activated protein C is reduced in young survivors of myocardial infarction and inversely correlates with the severity of coronary lesions. J Thromb Haemost 2006; 4: 1530-1536.
31. España F, Vayá A, Mira Y, et al. Low level of circulating activated protein C is a risk factor for venous thromboembolism. Thromb Haemost 2001; 86: 1368-1373.
32. Marlar R, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990; 16: 299-309.
33. Marlar RA, Montgomery RR, Broekmans AW. Diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the Subcommittee on Protein C and Protein S, International Committee on Thrombosis and Haemostasis. J Pediatr 1989; 114: 528-534.
34. Seligsohn U, Berger A, Abend M, et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 1984; 310: 559-562.
35. Branson HE, Katz J, Marble R, et al. Inherited protein C deficiency in a neonate. Lancet 1983; 2: 1165-1168.
36. Jackson C, Xue M, Thompson P, et al. Activated protein C prevents inflammation yet stimulates angiogenesis to promote cutaneous wound healing. Wound Repair Regen 2005; 13: 284-294.
37. Isobe H, Okajima K, Uchiba M, et al. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 2001; 104: 1171-1175.
38. Taylor F, Chang A, Esmon C, et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-925.
39. Iba T, Kidokoro A, Fukunaga M, et al. Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit Care Med 2005; 33: 368-372.
40. Xue M, Thompson P, Sambrook P, et al. Activated protein C stimulates expression of angiogenic factors in human skin cells, angiogenesis in the chick embryo and cutaneous wound healing in rodents. Clin Hemorheol Microcirc 2006; 34: 153-161.
41. Zlokovic B, Zhang C, Liu D, et al. Functional recovery after embolic stroke in rodents by activated protein C. Ann Neurol 2005; 58: 474-477.
42. Liu D, Cheng T, Guo H, et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 2004; 10: 1479-1483.
43. Cheng T, Petraglia A, Li Z, et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 2006; 12: 1278-1285.
44. Murakami K, Okajima K, Uchiba M, et al. Activated protein C attenuates endotoxin- induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996; 87: 642-647.
45. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. J Am Med Assoc 2003; 290: 238-247.
46. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. J Am Med Assoc 2001; 286: 1869-1878.
47. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
48. Martí-Carvajal A, Solà I, Lathyris D, et al. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2011; CD004388.
49. Coughlin S. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264.
50. Ossovskaya VS, Bunnet NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004; 84: 579-621.
51. Nakamura M, Gabazza E, Imoto I, et al. Anti-inflammatory effect of activated protein C in gastric epithelial cells. J Thromb Haemost 2005; 3: 2721-2729.
52. Bae J, Yang L, Rezaie A. Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proc Natl Acad Sci USA 2007; 104: 2867-2872.
53. Gorbacheva L, Davidova O, Sokolova E, et al. Endothelial protein C receptor is expressed in rat cortical and hippocampal neurons and is necessary for protective effect of activated protein C at glutamate excitotoxicity. J Neurochem 2009; 111: 967-975.
54. Gillibert-Duplantier J, Rullier A, Neaud V, et al. Liver myofibroblasts activate protein C and respond to activated protein C. World J Gastroenterol 2010; 16: 210-216.
55. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-3172.
56. Loubele ST, Spek CA, Leenders P, et al. Activated protein C protects against myocardial ischemia/reperfusion injury via inhibition of apoptosis and inflammation. Arterioscler Thromb Vasc Biol 2009; 29: 1087-1092.
57. Fernandez JA, Xu X, Liu D, et al. Recombinant murine activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis 2003; 30: 271-276.
58. Yang X, Banerjee Y, Fernandez J, et al. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. PNAS 2009; 106: 274-279.
59. Cao C, Gao Y, Li Y, et al. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin Invest 2010; 120: 1971-1980.
60. Xue M, Chow S, Dervish S, et al. Activated protein C enhances human keratinocyte barrier integrity via sequential activation of epidermal growth factor receptor and Tie2. J Biol Chem 2011; 286: 6742-6750.
61. Joyce DE, Gelbert L, Ciaccia A, et al. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199-11203.
62. Kerschen E, Hernandez I, Zogg M, et al. Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest 2010; 120: 3167-3178.
63. Mosnier L, Griffin J. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003; 373: 65-70.
64. Cheng T, Dong L, Griffin J, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003; 9: 338-342.
65. Guo H, Liu D, Gelbard H, et al. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 2004; 41: 563-572.
66. Riewald M, Petrovan R, Donner A, et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-1882.
67. Gateau-Roesch O, Argaud L, Ovize M. Mitochondrial permeability transition pore and postconditioning. Cardiovasc Res 2006; 70: 264-273.
68. Rodrigues S, Granger D. Role of blood cells in ischaemia-reperfusion induced endothelial barrier failure. Cardiovasc Res 2010; 87: 291-299.
69. Minhas N, Xue M, Fukudome K, et al. Activated protein C utilizes the angiopoietin/ Tie2 axis to promote endothelial barrier function. FASEB J 2009; 24: 873-881.
70. Bae JS, Yang L, Manithody C, et al. Engineering a disulfide bond to stabilize the calcium-binding loop of activated protein C eliminates its anticoagulant but not its protective signaling properties. J Biol Chem 2007; 282: 9251-9259.
71. Gale AJ, Sun X, Heeb MJ, et al. Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va. Protein science 1997; 6: 132-140.
72. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant - activated protein C. J Exp Med 2007; 204: 2439-2448.
73. Mosnier LO, Gale AJ, Yegneswaran S, et al. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood 2004; 104: 1740-1744.
74. Mosnier LO, Yang XV, Griffin JH. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem 2007; 282: 33022-33033.
75. Mosnier LO, Zampolli A, Kerschen EJ, et al. Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood 2009; 113: 5970-5978.
76. Sun Y, Tran S, Norstrøm E, et al. Enhanced rate of cleavage at Arg-306 and Arg-506 in coagulation factor Va by gla domain-mutated human-activated protein C. J Biol Chem 2004; 279: 47528-47535.
77. Sun YH, Shen L, Dahlbäck B. Gla domain-mutated human protein C exhibiting enhanced anticoagulant activity and increased phospholipid binding. Blood 2003; 101: 2277-2284.
78. Zhang L, Castellino F. The binding energy of human coagulation protein C to acidic phospholipid vesicles contains a major contribution from leucine 5 in the y-carboxyglutamic acid domain. J Biol Chem 1994; 269: 3590-3595.
79. Preston R, Ajzner E, Razzari C, et al. Multifunctional specificity of the protein C/activated protein C Gla domain. J Biol Chem 2006; 281: 28850-2887.
80. Christiansen W, Jalbert L, Robertson R, et al. Hydrophobic amino acid residues of human anticoagulation protein C that contribute to its functional binding to phospholipid Vesicles. Biochemistry 1995; 34: 10376-10382.
81. McDonald J, Shah A, Schwalbe R, et al. Comparison of naturally occurring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site. Biochemistry 1997; 36: 5120-5127.
82. Shen L, Shah A, Dahlbäck B, et al. Enhancing the activity of protein C by mutagenesis to improve the membrane-binding site: studies related to Proline-10. Biochemistry 1997; 36: 16025-16031.
83. Zhang L, Jhingan A, Castellino F. Role of individual?-carboxyglutamic acid residues of activated human protein C in defining its in vitro anticoagulant activity. Blood 1992; 80: 942-952.
84. Oganesyan V, Oganesyan N, Terzyan S, et al. The crystal structure of the endothelial protein C receptor and a bound phospholipid. J Biol Chem 2002; 277: 24851-24854.
85. Qureshi S, Yang L, Manithody C, et al. Functional properties and active-site topographies of factor X Gla- and prothrombin Gla-domain chimeras of activated protein C. Biochim Biophys Acta 2008; 1780: 1080-1086.
86. Preston R, Villegas-Mendez A, Sun Y, et al. Selective modulation of protein C affinity for EPCR and phospholipids by Gla domain mutation. FEBS J 2005; 272: 97-108.
87. Zhang L, Castellino F. A y-Carboxyglutamic Acid (y) Variant (y6D, y7D) of Human Activated Protein C Displays Greatly Reduced Activity as an Anticoagulant. Biochemistry 1990; 29: 10828-10834.
88. Zhang L, Castellino F. Role of the Hexapeptide Disulfide Loop Present in the y-Carboxyglutamic Acid Domain of Human Protein C in Its Activation Properties and in the in Vitro Anticoagulant Activity of Activated Protein C. Biochemistry 1991; 30: 6696-6704.
89. Gaussem P, Gandrille S, Duchemin J, et al. Influence of six mutations of the protein C gene on the Gla domain conformation and calcium affinity. Thromb Haemost 1994; 71: 748-754.
90. Gandrille S, Alhenc-Gelas M, Gaussem P, et al. Five novel mutations located in exons III and IX of the protein C gene in patients presenting with defective protein C anticoagulant activity. Blood 1993; 82: 159-168.
91. Bovill E, Tomczak J, Grant B, et al. Protein CVermont: symptomatic type II protein C deficiency associated with two GLA domain mutations. Blood 1992; 79: 1456-1465.
92. Thariath A, Castellino F. Highly conserved residue arginine-15 is required for the Ca2+-dependent properties of the gamma-carboxyglutamic acid domain of human anticoagulation protein C and activated protein C. Biochem J 1997; 322: 309-315.
93. Iijima K, Fukuda C, Nakamura K, et al. A new hereditary abnormal protein C (protein C Yonago) with a dysfunctional Gla-domain. Thromb Res 1991; 63: 249-257.
94. Mimuro J, Muramatsu S, Kaneko M, et al. An abnormal protein C (protein C Yonago) with an amino acid substitution of Gly for Arg-15 caused by a single base mutation of C to G in codon 57 (CGG-->GGG). Deteriorated calcium-dependent conformation of the gamma-carboxyglutamic acid domain relevant to a thrombotic tendency. Int J Hematol 1993; 57: 9-14.
95. Harmon S, Preston RJS, Ainle FN, et al. Dissociation of activated protein C functions by elimination of protein S cofactor enhancement. J Biol Chem 2008; 283: 30531-30539.
96. Rezaie A, Esmon C. The function of calcium in protein C activation by thrombin and the thrombin-thrombomodulin complex can be distinguished by mutational analysis of protein C derivatives. J Biol Chem 1992; 267: 26104-26109.
97. Ohlin A, Landes G, Bourdon P, et al. Beta-hydroxyaspartic acid in the first epidermal growth factor-like domain of protein C. Its role in Ca2+ binding and biological activity. J Biol Chem 1988; 263: 19240-19248.
98. Ohlin A, Björk I, Stenflo J. Proteolytic formation and properties of a fragment of protein C containing the gamma-carboxyglutamic acid rich domain and the EGF-like region. Biochemistry 1990; 29: 644-651.
99. Rezaie A, Esmon C. Proline at the P2 position in protein C is important for calcium- mediated regulation of protein C activation and secretion. Blood 1994; 83: 2526-2531.
100. Yang L, Prasad S, Di Cera E, et al. The conformation of the activation peptide of protein C is influenced by Ca2+ and Na+ binding. J Biol Chem 2004; 279: 38519-38524.
101. Grinnell B, Gerlitz B, Berg D. Identification of a region in protein C involved in thrombomodulin-stimulated activation by thrombin: potential repulsion at anion-binding site I in thrombin. Biochem J 1994; 303: 929-933.
102. Friedrich U, Nicolaes G, Villoutreix B, et al. Secondary substrate-binding exosite in the serine protease domain of activated protein C important for cleavage at Arg-506 but not at Arg-306 in factor Va. J Biol Chem 2001; 276: 2305-2308.
103. Gale A, Tsavaler A, Griffin J. Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. J Biol Chem 2002; 277: 28836-28840.
104. Friedrich U, Blom A, Dahlbäck B, et al. Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C. J Biol Chem 2001; 276: 24122-24128.
105. Gerlitz B, Grinnell B. Mutation of protease domain residues Lys37-39 in human protein C inhibits activation by the thrombomodulin-thrombin complex without affecting activation by free thrombin. J Biol Chem 1996; 271: 22285-22288.
106. Glasscock L, Gerlitz B, Coopera S, et al. Basic residues in the 37-loop of activated protein C modulate inhibition by protein C inhibitor but not by a1-antitrypsin. Biochim Biophys Acta 2003; 1649: 106-117.
107. Manithody C, Fay P, Rezaie A. Exosite-dependent regulation of factor VIIIa by activated protein C. Blood 2003; 101: 4802-4807.
108. Alhenc-Gelas M, Gandrille S, Aubry M, et al. Thirty-three novel mutations in the protein C gene. French INSERM network on molecular abnormalities responsible for protein C and protein S. Thromb Haemost 2000; 83: 86-92.
109. Vincenot A, Gaussem P, Pittet J, et al. Amino acids 225-235** of the protein C serine-protease domain are important for the interaction with the thrombinthrombomodulin complex. FEBS lett 1995; 367: 153-157.
110. Fuentes-Prior P, Iwanaga Y, Huber R, et al. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature 2000; 404: 518-525.
111. Fisher C, Greengard J, Griffin J. Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen. Protein Sci 1994; 3: 588-599.
112. Shen L, Villoutreix B, Dahlbäck B. Interspecies loop grafting in the protease domain of human protein C yielding enhanced catalytic and anticoagulant activity. Thromb Haemost 1999; 82: 1078-1087.
113. Yang L, Manithody C, Rezaie A. The functional significance of the autolysis loop in protein C and activated protein C. Thromb Haemost 2005; 94: 60-68.
114. Cramer T, Gale A. Function of the activated protein C (APC) autolysis loop in activated FVIII inactivation. Br J Haematol 2011; 153: 644-654.
115. Gale A, Heeb M, Griffin J. The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. Blood 2000; 96: 585-593.
116. Shen L, Dahlbäck B, Villoutreix B. Tracking structural features leading to resistance of activated protein C to 〈1-antitrypsin. Biochemistry 2000; 39: 2853-2860.
117. Shen L, Villoutreix B, Dahlbäck B. Involvement of Lys 62[217] and Lys 63[218] of Human Anticoagulant Protein C in Heparin Stimulation of Inhibition by the Protein C Inhibitor. Thromb Haemost 1999; 82: 72-79.
118. Yang L, Bae JS, Manithody C, et al. Identification of a Specific Exosite on Activated Protein C for Interaction with Protease-activated Receptor 1. J Biol Chem 2007; 282: 25493-25500.
119. Yegneswaran S, Kojima Y, Nguyen P, et al. Factor Va residues 311-325 represent an activated protein C binding region. J Biol Chem 2007; 282: 28353-28361.
120. Yang L, Manithody C, Rezaie A. Activation of protein C by the thrombin-thrombomodulin complex: Cooperative roles of Arg-35 of thrombin and Arg-67 of protein C. PNAS 2006; 103: 879-884.
121. Ní Ainle F, O'Donnell J, Johnson J, et al. Activated protein C N-linked glycans modulate cytoprotective signaling function on endothelial cells. J Biol Chem 2011; 286: 1323-1330.
122. Rezaie A, Esmon C. Conversion of glutamic acid 192 to glutamine in activated protein C changes the substrate specificity and increases reactivity toward macromolecular inhibitors. J Biol Chem 1993; 268: 19943-19948.
123. Soriano-Garcia M, Padmanabhan K, de Vos A, et al. The Ca2+ ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1. Biochemistry 1992; 31: 2554-2566.